Kura Oncology (NASDAQ:KURA) Given New $29.00 Price Target at Bank of America

Kura Oncology (NASDAQ:KURA - Free Report) had its price objective lowered by Bank of America from $36.00 to $29.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued reports about the stock. Jefferies Financial Group decreased their price target on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research note on Thursday. HC Wainwright lifted their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a "buy" rating in a research report on Thursday. Stifel Nicolaus lowered shares of Kura Oncology from a "buy" rating to a "hold" rating and cut their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Thursday. Finally, TD Cowen reissued a "buy" rating on shares of Kura Oncology in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $29.38.

Kura Oncology Price Performance

Shares of KURA traded up $0.74 during midday trading on Friday, reaching $10.80. The stock had a trading volume of 6,765,617 shares, compared to its average volume of 993,181. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $839.85 million, a price-to-earnings ratio of -4.66 and a beta of 0.86. The company's 50-day moving average is $18.08 and its 200 day moving average is $19.76. Kura Oncology has a 12-month low of $9.06 and a 12-month high of $24.17.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of KURA. Suvretta Capital Management LLC grew its holdings in shares of Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after acquiring an additional 583,155 shares during the period. Vanguard Group Inc. boosted its position in shares of Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company's stock valued at $86,726,000 after purchasing an additional 28,212 shares in the last quarter. Armistice Capital LLC grew its stake in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock worth $48,386,000 after purchasing an additional 302,000 shares during the period. Artal Group S.A. raised its holdings in Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company's stock worth $40,951,000 after purchasing an additional 151,828 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after buying an additional 41,535 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.